SGLT2 inhibitors had glucose-lowering effects comparable to those of DPP4 inhibitors but more favorable pleiotropic effects on body weight, ALT and eGFR changes, potentially improving type 2 diabetes patients’ cardio-metabolic disease risks (Cardiovascular Diabetology)
Diabetes News
Category: Medication
SGLT‐2 Inhibitor Renal Outcome Modification in Type‐2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk
While confirmatory of the exploratory data from CVOTs, CREDENCE provides the first robust data on the effects of canagliflozin on patient relevant renal endpoints. Extrapolation to a conclusion of a SGLT2 inhibitor class effect cannot be made until additional renal trials with other SGLT2 inhibitors are reported (Diabetes, Obesity and Metabolism)
Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
Sodium‐glucose cotransporter 2 inhibitors protect against cardiovascular disease and death in diverse subsets of patients with type 2 diabetes mellitus regardless of cardiovascular disease history (Journal of the American Heart Association)
Liraglutide as add‐on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial
Liraglutide significantly improved glycaemic control compared to placebo in patients with type 2 diabetes, insufficiently controlled with SGLT2is with/without metformin, with no unexpected safety findings (Diabetes, Obesity and Metabolism)
Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
EMPA effectively reduces hepatic fat in patients with T2D with excellent glycemic control and short known disease duration. Interestingly, EMPA also decreases circulating uric acid and raises adiponectin levels despite unchanged insulin sensitivity. EMPA could therefore contribute to the early treatment of nonalcoholic fatty liver disease in T2D (Diabetes Care)
Comparative effects of sulfonylureas, DPP4is and SGLT2 inhibitors added to metformin monotherapy: a propensity‐score matched cohort study in UK primary care
In routine care, SGLT2is have greater effects on cardiometabolic risk factors than SUs. Routine care data closely replicates the effects of diabetes drugs on physiological variables measured in clinical trials (Diabetes, Obesity and Metabolism)
Assessing the Risk for Gout With Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes
Adults with type 2 diabetes prescribed an SGLT2 inhibitor had a lower rate of gout than those prescribed a GLP1 agonist. Sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout among adults with type 2 diabetes mellitus, although future studies are necessary to confirm this observation (Annals of Internal Medicine)
Enhancement of the serum chloride concentration by administration of sodium–glucose cotransporter-2 inhibitor and its mechanisms and clinical significance in type 2 diabetic patients
The present study demonstrated that SGLT2i enhances the serum chloride concentration in T2DM patients and suggests that the effect is mediated by the possible following mechanisms: (Diabetology & Metabolic Syndrome)
Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells: A randomised, double-blind placebo-controlled feasibility trial
Sitagliptin increases eMSCs and decreases decidual senescence. A large-scale clinical trial evaluating the impact of preconception sitagliptin treatment on pregnancy outcome in RPL is feasible and warranted (EBioMedicine)
Fournier’s gangrene and sodium‐glucose co‐transporter‐2 inhibitors: A meta‐analysis of randomized controlled trials
Data from RCTs do not show an increased risk of FG among patients, unlike pharmacovigilance reports, but the number of recorded cases is small (Diabetes, Obesity and Metabolism)
Persistent whole day meal effects of three dipeptidyl peptidase‐4 inhibitors on glycemia and hormonal responses in metformin‐treated type 2 diabetes
DPP‐4 inhibition has persistent daytime effects on glucose, islet and incretin hormones with no difference between three different DPP‐4 inhibitors (Diabetes, Obesity and Metabolism)
Incretin‐based glucose‐lowering medications and the risk for acute pancreatitis and malignancies ‐ a meta‐analysis based on cardiovascular outcomes trials
Based on a large database of randomized, placebo‐controlled, prospective cardiovascular outcomes studies with GLP‐1 receptor agonists and DPP‐4 inhibitors, no signal for pancreatic cancer or any malignant neoplasms was detected. However, a 75% risk increase for development of an acute pancreatitis was seen in the meta‐analysis of DPP‐4 inhibitor CVOTs (Diabetes, Obesity and Metabolism)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes (NEJM)
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events
These results suggest that liraglutide treatment is associated with reduced total MACE compared with placebo among patients with type 2 diabetes and high risk of cardiovascular events. This analysis supports the findings of an absolute benefit of liraglutide treatment with respect to the overall burden of cardiovascular events in this high-risk patient population (JAMA Cardiology)
Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: a systematic review and meta-analysis of randomized controlled trials
This meta-analysis suggests that a GLP-1RA/SGLT-2i combination, if tolerated, exerts significant beneficial effects on glycemic control and body weight loss, however increasing the risk for any hypoglycemia and gastrointestinal adverse event (Diabetes Research and Clinical Practice)
Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety
Switching patients with type 1 diabetes to IDeg from other basal insulins was associated with relevant improvements in metabolic control and glycemic variability without weight gain; the risk of hypoglycemic episodes also significantly declined (Diabetes Therapy)
Oral semaglutide for type 2 diabetes: a systematic review and meta‐analysis
Oral semaglutide can effectively and safely reduce blood glucose, body weight and systolic blood pressure. Nevertheless, it is associated with increased incidence of gastrointestinal adverse events (Diabetes, Obesity and Metabolism)
Improving Type 2 Diabetes Management in General Practice Using a Second-Generation Basal Insulin Analogue Insulin Glargine 300 U/mL: A Practical Guide
The clinical application of the use of Gla-300 include advantages such as less intra- and interpatient variability in glucose control resulting in rather less hypoglycaemia, longer duration of action and greater flexibility in the timing of administration thus suiting a wide range of patient presentations (Diabetes Therapy)
Costarting sitagliptin with metformin is associated with a lower likelihood of disease progression in newly treated people with type 2 diabetes: a cohort study
Costarting drug therapy with sitagliptin and metformin was associated with a lower likelihood of disease progression in people with type 2 diabetes compared with adding sitagliptin later (Diabetic Medicine)
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
This comprehensive review covers the historical background, physiology, application in type 2 diabetes, novel uses, cardiovascular benefits, side effects and contraindications of sodium-glucose cotransporter-2 (SGLT2) inhibitors (Diabetes, Metabolic Syndrome and Obesity)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 39
- Next Page »
Glycosmedia is also available as an App: